Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Clinical utility of portable electrophysiology to measure fatigue in treatment-naïve non-small cell lung cancer.

O'Connor B, Markicevic M, Newman L, Poduval RK, Tiernan E, Hanrahan E, Cuffe S, Reilly RB, Walsh D.

Support Care Cancer. 2019 Jul;27(7):2617-2623. doi: 10.1007/s00520-018-4542-1. Epub 2018 Nov 22.

PMID:
30467793
2.

A snapshot of lipid levels in the Republic of Ireland in 2017.

Agar R, Markham C, Prendergast M, Canning R, Maher E, Finn C, Sammon N, Fall S, Fallon N, Hanrahan E, King L, Maher V.

Ir J Med Sci. 2019 Feb;188(1):241-247. doi: 10.1007/s11845-018-1820-3. Epub 2018 Jun 1.

PMID:
29858796
3.

Multiple cutaneous and uterine leiomyomata with features of benign metastasing leiomyomatosis: a novel mutation of the fumarate hydratase gene.

Gilhooley E, Fahy C, Hanrahan E, Keane M, Swan N, Lally A.

Clin Exp Dermatol. 2018 Apr;43(3):334-335. doi: 10.1111/ced.13332. Epub 2017 Dec 21. No abstract available.

PMID:
29266330
4.

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.

Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV.

Clin Cancer Res. 2017 Sep 15;23(18):5489-5501. doi: 10.1158/1078-0432.CCR-16-3216. Epub 2017 May 30.

5.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum in: Lancet Respir Med. 2018 Dec;6(12):e57.

PMID:
28408243
6.

Using cognitive-functional assessment to predict self-care performance of memory care tenants.

Schaber P, Klein T, Hanrahan E, Vencil P, Afatika K, Burns T.

Am J Alzheimers Dis Other Demen. 2013 Mar;28(2):171-8. doi: 10.1177/1533317512470206. Epub 2013 Jan 4.

PMID:
23293251
7.

Rapid needle-out patient-rollover time after percutaneous CT-guided transthoracic biopsy of lung nodules: effect on pneumothorax rate.

O'Neill AC, McCarthy C, Ridge CA, Mitchell P, Hanrahan E, Butler M, Keane MP, Dodd JD.

Radiology. 2012 Jan;262(1):314-9. doi: 10.1148/radiol.11103506. Epub 2011 Nov 21.

PMID:
22106349
8.

Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer.

Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA.

Breast J. 2011 Sep-Oct;17(5):462-9. doi: 10.1111/j.1524-4741.2011.01116.x. Epub 2011 Jul 5.

PMID:
21726347
9.

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV.

J Clin Oncol. 2010 Jan 10;28(2):193-201. doi: 10.1200/JCO.2009.22.4279. Epub 2009 Nov 30.

10.

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN.

J Clin Oncol. 2009 Dec 1;27(34):5700-6. doi: 10.1200/JCO.2009.23.2025. Epub 2009 Nov 2.

11.

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV.

Clin Cancer Res. 2009 May 15;15(10):3600-9. doi: 10.1158/1078-0432.CCR-08-2568. Epub 2009 May 15.

12.

A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.

Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES.

Am J Clin Oncol. 2009 Jun;32(3):274-9. doi: 10.1097/COC.0b013e318187dd57.

PMID:
19433965
13.

Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.

Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V.

J Clin Oncol. 2007 Nov 1;25(31):4952-60.

PMID:
17971593
14.
15.
16.

Labor epidural anesthetics comparing loss of resistance with air versus saline: does the choice matter?

Norman D, Winkelman C, Hanrahan E, Hood R, Nance B.

AANA J. 2006 Aug;74(4):301-8. Erratum in: AANA J. 2006 Dec;74(6):424.

PMID:
16918122
17.

Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor.

Blancas I, García-Puche JL, Bermejo B, Hanrahan EO, Monteagudo C, Martínez-Agulló A, Rouzier R, Hennessy BT, Valero V, Lluch A.

Ann Oncol. 2006 Nov;17(11):1644-9. Epub 2006 Jul 27.

PMID:
16873428
18.

Doctor of nursing practice: forward direction or digression for child psychiatric nursing?

Scahill L, Hamrin V, Pachler M, Rains A, Hanrahan E, Koenig K.

J Child Adolesc Psychiatr Nurs. 2006 May;19(2):49-50. No abstract available.

PMID:
16671918
19.

Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.

Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN.

J Clin Oncol. 2006 May 1;24(13):2113-22. Review.

PMID:
16648513
20.

Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.

Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN.

Cancer. 2006 Jun 1;106(11):2327-36.

21.

Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.

Hanrahan EO, Hennessy BT, Valero V.

Expert Opin Pharmacother. 2005 Aug;6(9):1477-91. Review.

PMID:
16086636
22.

Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.

Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E.

Cancer. 2005 Sep 15;104(6):1158-71.

23.

Cisplatin as a radiosensitizer in the treatment of locally advanced head and neck cancer.

Altundag O, Altundag K, Morandi P, Hanrahan E.

Oral Oncol. 2005 Apr;41(4):435. No abstract available.

PMID:
15792617
24.

Non-Hodgkin lymphoma: an update.

Hennessy BT, Hanrahan EO, Daly PA.

Lancet Oncol. 2004 Jun;5(6):341-53. Review.

PMID:
15172354
25.

Chemotherapy options for the elderly patient with advanced non-small cell lung cancer.

Hennessy BT, Hanrahan EO, Breathnach OS.

Oncologist. 2003;8(3):270-7. Review.

26.

Aqueous dissociation constants of 5-halo-8-hydroxyquinolines.

Chakrabarty MR, Hanrahan ES, Heindel ND, Watts GF.

Anal Chem. 1967 Feb;39(2):238-41. No abstract available.

PMID:
6040695
27.

Use of vitamin E in the treatment of keloids.

EDGERTON MT Jr, HANRAHAN EM, DAVIS WB.

Plast Reconstr Surg (1946). 1951 Sep;8(3):224-33. No abstract available.

PMID:
14882943
28.

Mammaplasty; the one-stage transposition operation.

HANRAHAN EM.

Plast Reconstr Surg (1946). 1950 Aug;6(2):110-8. No abstract available.

PMID:
15440332
29.

The use of a migrated skin flap for both lining and covering of an artificial antethoracic esophagus.

HANRAHAN EM.

Plast Reconstr Surg (1946). 1947 Sep;2(5):474-80. No abstract available.

PMID:
20266113
30.

The experimental investigation of peptic ulcer.

HANRAHAN EM.

Bull Johns Hopkins Hosp. 1947 Aug;81(2):131-49. No abstract available.

PMID:
20264755
31.

The split-thickness skin graft as a covering following removal of a fingernail.

HANRAHAN EM.

Surgery. 1946 Sep;20:398-400. No abstract available.

PMID:
20997884
32.
33.

RESULTS OF TREATMENT BY AUTOGENOUS GLAND FILTRATE IN HODGKIN'S DISEASE.

Hanrahan EM.

Ann Surg. 1930 Jul;92(1):23-34. No abstract available.

34.

THE SURGICAL TREATMENT OF DUODENAL ULCER: END-RESULTS OVER A TWENTY-FIVE YEAR PERIOD.

Finney JM, Hanrahan EM.

Ann Surg. 1929 Nov;90(5):904-17. No abstract available.

35.

CHOLESTEATOMATOUS CYSTS: WITH REPORT OF CASE INVOLVING THE MAXILLA.

Finney JM, Hanrahan EM.

Ann Surg. 1926 Aug;84(2):295-301. No abstract available.

36.

SPLENIC BLOOD DISORDERS: A SURGICAL CLASSIFICATION WITH REFERENCE TO SPLENECTOMY.

Hanrahan EM.

Ann Surg. 1925 May;81(5):906-10. No abstract available.

Supplemental Content

Loading ...
Support Center